POGLIANI, ENRICO MARIA
 Distribuzione geografica
Continente #
NA - Nord America 8.523
EU - Europa 3.440
AS - Asia 1.010
Continente sconosciuto - Info sul continente non disponibili 15
SA - Sud America 8
AF - Africa 5
OC - Oceania 4
Totale 13.005
Nazione #
US - Stati Uniti d'America 8.348
DE - Germania 709
SE - Svezia 616
CN - Cina 610
IE - Irlanda 608
UA - Ucraina 530
IT - Italia 421
HK - Hong Kong 241
GB - Regno Unito 188
CA - Canada 172
FI - Finlandia 122
FR - Francia 59
IN - India 53
RU - Federazione Russa 43
DK - Danimarca 34
NL - Olanda 29
VN - Vietnam 28
BE - Belgio 27
AT - Austria 25
SG - Singapore 21
TR - Turchia 20
JP - Giappone 19
EU - Europa 14
ES - Italia 6
RO - Romania 6
BR - Brasile 5
BG - Bulgaria 4
IR - Iran 4
KR - Corea 4
SA - Arabia Saudita 4
AU - Australia 3
ID - Indonesia 3
PL - Polonia 3
HU - Ungheria 2
MA - Marocco 2
MX - Messico 2
A2 - ???statistics.table.value.countryCode.A2??? 1
CH - Svizzera 1
CO - Colombia 1
CU - Cuba 1
EC - Ecuador 1
EE - Estonia 1
EG - Egitto 1
HR - Croazia 1
LT - Lituania 1
MD - Moldavia 1
MK - Macedonia 1
MU - Mauritius 1
MZ - Mozambico 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
PK - Pakistan 1
PT - Portogallo 1
SR - Suriname 1
TH - Thailandia 1
UZ - Uzbekistan 1
Totale 13.005
Città #
Ann Arbor 1.839
Woodbridge 1.038
Houston 740
Fairfield 647
Dublin 596
Jacksonville 588
Chandler 457
Ashburn 429
Frankfurt am Main 377
Wilmington 367
Dearborn 323
Seattle 251
Hong Kong 241
New York 238
Princeton 224
Cambridge 207
Milan 139
Nanjing 127
Lawrence 103
Lachine 102
Altamura 100
Beijing 93
Shanghai 89
Göttingen 52
Nanchang 42
Andover 37
Shenyang 32
Changsha 31
San Diego 31
Toronto 31
Guangzhou 29
Hebei 28
Ottawa 28
Brussels 27
Vienna 24
Huizen 22
Boardman 21
Helsinki 19
Fürstenwalde 18
Fremont 17
Jiaxing 17
London 17
Lissone 16
Norwalk 16
Redmond 16
Los Angeles 15
Nürnberg 15
University Park 15
Jinan 14
Tianjin 14
Hangzhou 13
Hefei 13
Kunming 13
Mountain View 13
Pune 13
Chicago 12
Zhengzhou 10
Falls Church 9
Auburn Hills 8
Dong Ket 8
Edmonton 8
Rome 8
Bologna 6
Brescia 6
Buffalo 6
San Mateo 6
Washington 6
Leawood 5
Mumbai 5
Omegna 5
Taizhou 5
Chelsea 4
Gorgonzola 4
Haikou 4
Jeddah 4
Kiev 4
Kilburn 4
Kocaeli 4
Plovdiv 4
Simi Valley 4
Bengaluru 3
Bonndorf 3
Chongqing 3
Cinisello Balsamo 3
Cutrofiano 3
Desio 3
Detroit 3
Hounslow 3
Jakarta 3
Madrid 3
Monmouth Junction 3
Montréal 3
Munich 3
Ningbo 3
Prescot 3
Sacramento 3
Taiyuan 3
Bolzano 2
Casablanca 2
Caserta 2
Totale 10.230
Nome #
Increased tissue factor pathway inhibitor and homocysteine in Alzheimer's disease 383
A randomized clinical trial of ceftriaxone and amikacin versus piperacillin tazobactam and amikacin in febrile patients with hematological neoplasia and severe neutropenia 366
Treatment of Graft versus Host Disease with Mesenchymal Stromal Cells: A Phase I Study on 40 Adult and Pediatric Patients 308
Multicenter Independent Assessment of Outcomes in Chronic Myeloid Leukemia Patients Treated With Imatinib 286
Imatinib Long-Term Effects Study: Global Independent Assessment of Imatinib in Chronic Myeloid Leukemia: Results At 8 Years 285
Imatinib long term effects study: three years of follow-up and assessment 253
A boost of CD34+-selected peripheral blood cells without further conditioning in patients with poor graft function following allogeneic stem cell transplantation 233
Safe and Effective Treatment of Graft Versus Host Disease with Platelet Lysate-Expanded Human Mesenchymal Stromal Cells: A Phase 1 Study On 47 Adult and Pediatric Patients 233
GMP-grade preparation of biomimetic scaffolds with osteo-differentiated autologous mesenchymal stromal cells for the treatment of alveolar bone resorption in periodontal disease 204
Recurrent SETBP1 mutations in atypical chronic myeloid leukemia 201
Repeated infusions of donor-derived cytokine-induced killer cells in patients relapsing after allogeneic stem cell transplantation: A phase I study 186
A prospective study on cardiovascular events after acute pulmonary embolism 177
Good outcome for very high risk adult B-cell acute lymphoblastic leukaemia carrying genetic abnormalities t(4;11)(q21;q23) or t(9;22)(q34;q11), if promptly submitted to allogeneic transplantation, after obtaining a good molecular remission 177
Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis 177
Development of polycythemia vera after chemotherapy-induced remission of acute myeloid leukemia: a case report 168
The achievement of durable complete cytogenetic remission in late chronic and accelerated phase patients with CML treated with Imatinib mesylate predicts for prolonged response at 6 years 161
CML Patients Present Additional Mutations in Cancer Related Genes When Tested At Diagnosis 161
Thrombosis of the splenoportal axis after splenectomy 160
Long-term follow-up of patients with intermediate or high-grade non-Hodgkin lymphoma treated with a combination of cyclophosphamide, epirubicin, vincristine, and prednisone 158
Severe, reversible nelarabine-induced neuropathy and myelopathy 156
Rituximab prevents recurrence of thrombotic thrombocytopenic purpura: A case report 155
BCR AND BCR-ABL REGULATION DURING MYELOID DIFFERENTIATION IN HEALTHY DONORS AND CHRONIC PHASE-BLAST CRISIS CML PATIENTS 154
A CASE OF ATYPICAL PROLONGED HEMATOLOGIC TOXICITY WITH AZACITIDINE IN CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML), REVIEW OF LITERATURE AND A PROPOSAL OF MANAGEMENT 152
Circulating endothelial cells and endothelial activation in essential thrombocythemia: Results from CD146(+) immunomagnetic enrichment-flow cytometry and soluble E-selectin detection 148
Autoimmune hepatitis presenting as imatinib toxicity: description of a case and of therapeutic alternatives 146
Results of a lymphoblastic leukemia-like chemotherapy program with risk-adapted mediastinal irradiation and stem cell transplantation for adult patients with lymphoblastic lymphoma 144
NPM/ALK binds and phosphorylates the RNA/DNA binding protein PSF in anaplastic large cell lymphoma 141
Mechanisms of resistance to imatinib in chronic myeloid leukemia (CML) patients in chronic phase (CP) who achieved durable complete cytogenetic responses (CCR) 138
BCR and BCR-ABL regulation during myeloid differentiation in healthy donors and in chronic phase/blast crisis CML patients 137
High response rate and improvement of long-term survival with combined treatment modalities in patients with poor-risk primary thyroid diffuse large B-cell lymphoma: an International Extranodal Lymphoma Study Group and Intergruppo Italiano Linfomi study 134
Recurrent preeclapsia: The role of acquired and heritable thrombophilia 133
Recurrent SETBP1 Mutations in Atypical Chronic Myeloid Leukemia 133
Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma 132
Extracorporeal photochemotherapy for the treatment of chronic graft-versus-host disease: trend for a possible cell dose-related effect? 130
Role of radiotherapy in patients with early-stage diffuse large B-cell lymphoma of Waldeyer's ring in remission after anthracycline-containing chemotherapy 130
AIDA 0493 protocol for newly diagnosed acute promyelocytic leukemia: very long-term results and role of maintenance 130
Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial 129
A randomized comparison of caspofungin versus antifungal prophylaxis according to investigator policy in acute leukaemia patients undergoing induction chemotherapy (PROFIL-C study) 129
Crizotinib in anaplastic large-cell lymphoma 129
Combined prophylactic low-molecular weight heparin and low dose aspirin reduces the occurrences of adverse pregnancy outcome in multiparous women with preeclampsia and intrauterine fetal growth restriction in antecedent pregnancy 128
Platelet activation during plasma-reduced multicomponent PLT collection: A comparison between COBE Trima and Spectra LRS turbo cell separators 128
CD20 expression has no prognostic role in Philadelphia-negative B-precursor acute lymphoblastic leukemia: new insights from the molecular study of minimal residual disease 127
Imatinib dose increase up to 1200 mg daily can induce new durable complete cytogenetic remissions in relapsed Ph+ chronic myeloid leukemia patients 125
Second malignancy after treatment of adult acute myeloid leukemia: cohort study on adult patients enrolled in the GIMEMA trials 124
Management of bleeding in acquired hemophilia A: results from the European Acquired Haemophilia (EACH2) Registry 123
Imatinib failed to eradicate chronic myeloid leukemia in a patient with minimal residual disease 122
Demographic and clinical data in acquired hemophilia A: results from the European Acquired Haemophilia Registry (EACH2) 119
Hydroxyurea-related toxicity in 3,411 patients with Ph'-negative MPN 118
Increased risk of recurrent thrombosis in patients with essential thrombocythemia carrying the homozygous JAK2 V617F mutation 118
Prevention of venous thromboembolism in immobilized neurological patients: Guidelines of the Italian Society for Haemostasis and Thrombosis (SISET) 118
High versus standard dose methylprednisolone in the acute phase of idiopathic thrombotic thrombocytopenic purpura: A randomized study 117
Final results of a multicenter trial addressing role of CSF flow cytometric analysis in NHL patients at high risk for CNS dissemination 114
Complement activation: the missing link between ADAMTS-13 deficiency and microvascular thrombosis of thrombotic microangiopathies 112
ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned 112
HOMOZYGOSITY FOR JAK2V617F IDENTIFIES MPD PATIENTS WITH A MORE SYMPTOMATIC DISEASE A RETROSPECTIVE STUDY ON 989 PATIENTS FROM THE GIMEMA-MPD WORKING PARTY 110
Development of c-Kit-expressing Small-Cell lung Cancer in a Chronic Myeloid Leukemia Patient During Imatinib Treatment 107
Chemotherapy-phased imatinib pulses improve long-term outcome of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: Northern Italy Leukemia Group protocol 09/00 106
A case of Philadelphia Positive Acute Lymphoblastic Leukaemia with three different phenotypic lineage, each one presenting the same BCR-ABL hybrid transcript 104
Gemtuzumab ozogamicin (Mylotarg) as a single agent for molecularly relapsed acute promyelocytic leukemia 104
Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA Group 104
From Vaquez to Dameshek through JAK…2 much for polycythemia vera to be feared? 104
Rituximab as pre-emptive treatment in patients with thrombotic thrombocytopenic purpura and evidence of anti-ADAMTS13 autoantibodies 102
Resistance Profile of the BCR/ABL Inhibitor Bosutinib Using a High Throughput random Mutagenesis Assay 101
Fully immunocompetent CD8+ T lymphocytes are present in autologous haematopoietic stem cell transplantation recipients despite an ineffectual T-helper response 100
Venous thromboembolism and cancer: Guidelines of the Italian Association of Medical Oncology (AIOM) 99
Neurological symptoms in essential thrombocythemia: Impact of JAK2V617F mutation and response to therapy 98
SIGNIFICANT REDUCTION IN FASTING BLOOD GLUCOSE IN NONDIABETIC PH+ CHRONIC MYELOID LEUKEMIA PATIENTS TREATED WITH IMATINIB MESYLATE 97
Antithrombotic prophylaxis in multiparous women with preeclampsia or intrauterine growth retardation in an antecedent pregnancy 95
Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL) 95
Cytomegalovirus infection after autologous stem cell transplantation: incidence and outcome in a group of patients undergoing a surveillance program 93
Reviewed diagnosis of primary and secondary immune thrombocytopenic purpura in 79 adult patients hospitalized in 2000-2002 93
Cytarabine and clofarabine after high-dose cytarabine in relapsed or refractory AML patients 93
CLIPI: a new prognostic index for indolent cutaneous B cell lymphoma proposed by the International Extranodal Lymphoma Study Group (IELSG 11) 93
Frozen-and-thawed allogeneic platelet gels for treating postoperative chronic wounds 92
Role of BCL2L10 methylation and TET2 mutations in higher risk myelodysplastic syndromes treated with 5-azacytidine 90
Incidence of thrombotic complications in patients with haematological malignancies with central venous catheters: A prospective multicentre study 87
Valproic acid at therapeutic plasma levels may increase 5-azacytidine efficacy in higher risk myelodysplastic syndromes 87
Management of poor peripheral blood stem cell mobilization: Incidence, predictive factors, alternative strategies and outcome. A retrospective analysis on 2177 patients from three major Italian institutions 87
Immunoglobulin M monoclonal gammopathies of undetermined significance and indolent Waldenström's macroglobulinemia recognize the same determinants of evolution into symptomatic lymphoid disorders: Proposal for a common prognostic scoring system 84
Peg-filgrastim versus filgrastim after autologous stem cell tranplantation: case-control study in patients with multiple myeloma and review of the literature 82
Corticosteroids can reverse severe imatinib-induced hepatotoxicity 79
Leukocytosis is a risk factor for recurrent arterial thrombosis in young patients with polycythemia vera and essential thrombocythemia 77
Transplant-finalized salvage of adult acute lymphoblastic leukemia: results of a mitoxantrone- and methotrexate-based regimen in 36 patients 74
The host genetic background of DNA repair mechanisms is an independent predictor of survival in diffuse large B-cell lymphoma 74
Allogeneic transplantation following a reduced-intensity conditioning regimen in relapsed/refractory peripheral T-cell lymphomas: long-term remissions and response to donor lymphocyte infusions support the role of a graft-versus-lymphoma effect 74
Analysis of the host pharmacogenetic background for prediction of outcome and toxicity in diffuse large B-cell lymphoma treated with R-CHOP21 74
Extracorporeal photopheresis for the treatment of steroid refractory acute GVHD 73
Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage 72
In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate' [2] 70
Primary plasma cell leukemia: a retrospective multicenter study of 73 patients 70
Imatinib concentrations in human milk 68
Recurrent thrombosis in patients with polycythemia vera and essential thrombocythemia: Incidence, risk factors, and effect of treatments 67
Allogeneic stem cell transplantation following reduced-intensity conditioning can induce durable clinical and molecular remissions in relapsed lymphomas: pre-transplant disease status and histotype heavily influence outcome 67
Peripheral blood progenitor cell collection in chronic myeloid leukemia patients with complete cytogenetic response after treatment with imatinib mesylate 66
Advanced mast cell disease: an Italian Hematological Multicenter experience 65
Iron chelation therapy with deferasirox in the management of iron overload in primary myelofibrosis 65
Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study 64
Mast cell leukemia: A report of ten cases 64
The effect of prior exposure to imatinib on transplant-related mortality 62
Quality of life in elderly patients with essential thrombocythaemia. An Italian multicentre study 61
Totale 12.755
Categoria #
all - tutte 41.951
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 41.951


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/2019484 0 0 0 0 0 0 0 0 0 0 253 231
2019/20202.888 363 224 207 185 250 308 463 219 294 136 197 42
2020/20211.660 134 84 238 214 107 108 168 100 176 180 66 85
2021/20221.088 50 58 90 111 85 103 42 85 71 92 106 195
2022/20232.038 293 671 195 163 127 311 17 79 109 6 34 33
2023/20241.539 38 45 54 78 244 490 341 47 174 13 15 0
Totale 13.327